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Abstract
The family of platelet-derived growth factors (PDGFs) plays a number of critical roles in normal embryonic development,
cellular differentiation, and response to tissue damage. Not surprisingly, as it is a multi-faceted regulatory system, numerous
pathological conditions are associated with aberrant activity of the PDGFs and their receptors. As we and others have shown,
human gliomas, especially glioblastoma, express all PDGF ligands and both the two cell surface receptors, PDGFR-a and -b.
The cellular distribution of these proteins in tumors indicates that glial tumor cells are stimulated via PDGF/PDGFR-a
autocrine and paracrine loops, while tumor vessels are stimulated via the PDGFR-b. Here we summarize the initial discoveries
on the role of PDGF and PDGF receptors in gliomas and provide a brief overview of what is known in this ﬁeld.
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Introduction
Gliomas are the most common form of primary
malignancies of the central nervous system (CNS)
mainly affecting adults. These tumors have a histo-
logical resemblance to different types of glial cells and
are categorized into astrocytomas, oligodendroglio-
mas, oligoastrocytomas, and ependymomas, based
on the predominant cell type(s) in the respective
tumor (1).
Initial discovery and extensive studies of the epi-
dermal growth factor (EGF) and transforming growth
factor alpha (TGF-a), as well as the platelet-
derived growth factor (PDGF) family, revealed their
presence in glioblastoma cell cultures and tissues.
These growth factors, by signaling via their cell sur-
face tyrosine kinase receptors, EGFR and PDGFR-a
and -b, were able not only to induce normal mitogenic
and migratory responses, but when aberrantly
activated they were also able to transform cells.
Knowledge gained from in vitro experiments was
transferred to in vivo systems, and several mouse
models were created showing that gliomas can be
induced by forced expression of PDGF-B in the
brain. However, treatment with single tyrosine kinase
inhibitors (TKIs) given to glioma patients has gener-
ally not been successful.
Ever since the initial discoveries, investigations on
the molecular mechanisms and signaling pathways
involved in glioma have provided a more detailed
insight into the key events behind brain tumor initi-
ation, maintenance, and progression and have
resulted in signiﬁcantly improved cancer drug discov-
eries. However, the prognosis for patients with aggres-
sive brain tumors is still very poor. One intriguing
hypothesis is that glioblastoma resistance to therapy
and its rapid recurrence is due to the presence of a
subpopulation of tumor cells displaying stem cell
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gate the whole tumor. In this context, we brieﬂy
discuss the concept of cancer stem cells (CSCs) in
glioma.
PDGF/PDGFR
Discovered as a serum growth factor for ﬁbroblasts,
smooth muscle cells, and glial cells, the PDGF family
has become one of the most extensively studied
growth factor families (2-6). PDGF-B and -A were
discovered ﬁrst, while PDGF-C and -D were identi-
ﬁed decades later, based on gene homology searches.
PDGFs are members of the evolutionary conserved
family of structurally and functionally related PDGF/
VEGF growth factors. The PDGF family now
includes ﬁve dimeric proteins: PDGF-AA, -AB,
-BB, -CC, and -DD. The mammalian PDGF genes
are situated on different chromosomes and have
mostly independent transcriptional regulation and
thus distinct tissue- and time-speciﬁc gene expression
patterns in vivo. However, the overlapping expression
patterns of PDGF-A and -C suggest the possibility of
common transcriptional regulatory mechanisms (6).
All PDGFs have a highly conserved growth factor
domain, called the PDGF/VEGF homology domain.
This domain is involved in forming inter- and intra-
molecule disulphide bridges to form the PDGF
dimers (7). In order to be activated, a short
N-terminal extension present in PDGF-A and
PDGF-B has to undergo intracellular proteolytic
processing. PDGF-C and PDGF-D have a distinct
protein domain as part of their N-terminal extension,
called the CUB domain (7), preventing ligand–
receptor binding until cleaved and are activated by
extracellular proteases (8,9). The C-termini of
PDGF-C and -D lack amino acid sequence exten-
sions, while both PDGF-A and -B have a stretch of
basic amino acids that are mainly involved in extra-
cellular matrix (ECM) binding (10,11). There are two
functionally distinct isoforms of the A-chain due to
alternative splicing of exon 6, which encodes the
C-terminal stretch: the short form of PDGF-A
(PDGF-AS) lacks the positively charged retention
motif and is freely diffusible, while the long form
(PDGF-AL) can attach to the ECM with the help
of its C-terminal tail (2,12,13). The exact role of
PDGF-AL and how it functionally differs from the
shorter isoform is not well understood.
The ﬁve dimeric PDGF ligands act via the two cell
surface tyrosine kinase (RTK) receptors, PDGFR-a
and PDGFR-b (Figure 1). The PDGFRs have a
common domain structure, including ﬁve extracellu-
lar immunoglobulin (Ig)-like domains and a split
intracellular tyrosine kinase domain (6,14). As a result
of ligands binding to the receptors, homo- and het-
erodimerization of the receptors occur. This in turn
leads to transphosphorylation of the intracellular
domains and receptor activation. Once activated,
intracellular mediators dock to phosphotyrosine resi-
dues in the receptor, which leads to downstream
activation of intracellular signaling pathways. The
ability of each of the ﬁve dimeric PDGF ligands to
bind and activate the two PDGF receptors is quite
speciﬁc as summarized in Figure 1.
Our early studies on PDGF in glioma
The initial discoveries on the role of PDGF and
PDGF receptors in cancer came substantially from
studies on human brain tumors. Our efforts in this
ﬁeld of research began in 1981 when Monica Nistér
with Bengt Westermark was introduced to the vibrant
and fruitful collaboration formed by Westermark,
Wasteson, and Heldin. Carl-Henrik Heldin had puri-
ﬁed and characterized human PDGF-AB from plate-
lets (15). It had been shown that ﬁbroblasts, smooth
muscle cells, and glial cells were responsive to PDGF
(3–5), and the outstanding question was whether
PDGF was involved in human cancer.
Pontén and Westermark had established a large
number of human glioma cell lines that were suitable
to reveal if PDGF was produced by these cancer cells.
One such biopsy was the U-343 MG biopsy for which
a few clonal derivatives existed. Some cultures were
GFAP
+/astrocyte-like, while others had mesenchymal
features (16,17). The strategy used by Nistér et al. was
to screen conditioned media from U-343 MGa
Cl2 cells using the
125I-PDGF-binding assay on ﬁbro-
blasts to identify PDGF receptor competing activity.
Much to our excitement, such activity was detected,
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Figure 1. Receptor binding speciﬁcity of ﬁve dimeric PDGF
ligands. *Ligand DD can activate ab with lower speciﬁcity.
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presence of a secreted PDGF-like activity (18).
Further puriﬁcation and characterization attributed
this activity to a 31-kDa dimeric protein with struc-
tural, functional, and immunological similarities to
PDGF (19).
At this time, Wong-Staal and co-workers had
already reported a human gene homologous to
v-sis, simian sarcoma virus (SSV) oncogene (20).
But it was not until PDGF was sequenced in 1983
that the homology between the PDGF B-chain
and p28v-sis was revealed and PDGFB (c-sis) was
identiﬁed as a proto-oncogene (21). The cell surface
receptor for PDGF, now known as the PDGF
b-receptor, was found to be a tyrosine kinase (22).
Similarly, EGFR was a tyrosine kinase, homologous
to the v-erbB oncogene (23). These groundbreaking
ﬁndings brought a lot of interest to the ﬁeld, which
was spurred by the homology between p28v-sis and
PDGF-B and by the fact that SSV originally had been
isolated from a ﬁbrosarcoma in a woolly monkey (24).
When tested on ﬁbroblasts and other normal cell
types, the PDGF protein isolated from glioma-
conditioned media showed receptor-binding charac-
teristics and biological effects different from those of
PDGF-BB and -AB. It inhibited PDGF-BB-induced
chemotaxis and actin reorganization and had a lower
mitogenic activity than PDGF-AB puriﬁed from pla-
telets (25). These ﬁndings were initially challenged
but could later be conﬁrmed by other groups and
explained by the presence of a second receptor for
PDGF. Further work identiﬁed the puriﬁed glioma-
derived activity as PDGF-AA. Thereafter it was dis-
covered that glioma cells produced PDGF-AA, -AB,
and -BB dimeric proteins (26).
Human PDGFA was cloned by Betsholtz et al. after
generating a cDNA library from a clonal glioma cell
line, U-343 MGa Cl2:6, that produced high amounts
of PDGF receptor-competing activity. The isolated
cDNA included two splice variants of PDGF-A, a
short form (PDGF-AS) and a long form (PDGF-AL),
which in the latter case includes a 69 base pair (bp)
extension from exon 6, that codes for a C-terminal
stretch of basic amino acids (13,27,28). While the
PDGFB gene was localized on chromosome 22, the
PDGFA gene was found to be residing on chromo-
some 7.
By sub-cloning cells from the U-343 MGa cell line,
Nistér et al. identiﬁed an extensive clonal variation in
the amount of PDGF secreted by glioma cells and also
a clonal variation in the capacity of glioma cells to bind
125I-PDGF (29). The cells growth rate in serum-
free medium correlated to the amount of PDGF pro-
duced bythem.The mostprominent PDGFproducers
were also ‘immature’, tightly growing cells, while
clones with large, glia-like cells showed the highest
125I-PDGF-binding capacity. Thus, there was a neg-
ative correlation between the levels of PDGF secreted
from the cells and their capacity to bind the factor.
By Northern blot analysis, using a PDGFR-b cDNA
sequence as a probe, Nistér et al. identiﬁed PDGFR-b
mRNA in some of the glioma cell lines and clones.
Interestingly, the U-343 cell clones with the highest
capacity to bind
125I-PDGF-AA displayed a different-
sized PDGF receptor mRNA. Claesson-Welsh et al.
were then able to identify the second PDGF receptor,
PDGFR-a, expressed in U-343 MGa 31L cells (30).
Further interest came when the PDGFR-a cDNA was
cloned (31,32). Using
125I-binding assays, the pres-
ence of both PDGF receptors and EGF receptors on
human glioma cells was also described (33).
With the new cDNA, mRNA, and antibody
reagents available at Heldin’s laboratory that recog-
nized PDGFs and their receptors, investigation into
distribution was commenced using human brain
tissue, in collaboration with Keiko Funa. Using
mRNA in situ hybridization, high levels of both
PDGF-B and PDGFR-b mRNA were found on the
characteristic glioblastoma vasculature, while the glial
tumor cells expressed more PDGF-A mRNA(34).
This was conﬁrmed by a study of all glioma grades,
where it was also observed that the PDGFR-a was
present on glial tumor cells but not on the vasculature.
Much to our excitement, it was shown that PDGFRA
was overexpressed already in low-grade diffuse astro-
cytomas and further enhanced in high-grade tumors.
The ﬁndings indicated the presence of PDGF auto-
crine/paracrine loops stimulating glioma cells via the
a-receptor, and a PDGF-B autocrine loop stimulat-
ing the vasculature via the b-receptor (35). PDGFRA
expression was examined in a larger number of glioma
samples of different malignancy grades (36). Increa-
sed levels of PDGFR-a mRNA were observed in all
grades, but glioblastoma expressed the highest levels.
Only 16% of glioblastomas showed PDGFRA ampli-
ﬁcation, which suggested that other mechanisms were
responsible for PDGFRA overexpression in the
majority of tumors. The latter has also been indicated
by more recent studies (37,38). PDGFRA expression
correlated to loss of heterozygosity (LOH) on chro-
mosome 17p, where the TP53 gene is localized (36).
PDGFRA ampliﬁcation had been described by
Fleming et al. (39) and was conﬁrmed by Hermanson
et al. (36). More recently it has been reported
that PDGF-C and -D are also present in human
glioma (40).
The testing of the ﬁrst generation of TKIs, that
were more or less speciﬁc for the PDGF receptors,
was disappointing. The inhibitors did not signiﬁcantly
alter the in vitro growth of glioma cells. Moreover,
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transform ﬁbroblasts in vitro, PDGF-A could not
(41). Whether this could be attributed to the presence
or absence of the C-terminal stretch of basic amino
acids was unclear at the time. In addition, the inhibi-
tory effect of PDGF-A on PDGF-B-mediated cell
proliferation and motility was puzzling, and the sig-
niﬁcance of PDGF-A/a-receptor signaling in tumor
development was in question.
Although autocrine stimulation was extensively
studied at the time, its signiﬁcance in cancer was
difﬁcult to ﬁnally prove. However, the transforming
effect of PDGF in glioma cells was indicated by the
inhibitory effects of PDGF-BB antibodies (42) and by
studies using a truncated PDGF b-receptor (43).
Even now, clinical trials using TKIs fail to show
signiﬁcant therapeutic effects in patients (44,45).
Our recent investigations, performed in collabora-
tion with Arne Östman, Johan Holmberg, and Jonas
Muhr, have shed some light on the glioma cell resis-
tance to TKI inhibitors. Using tumor material
explanted from a number of human glioblastomas,
two different subtypes of glioma cultures, type A and
type B, were identiﬁed. Whereas type B cultures
showed mesenchymal features and were responsive
to mono-treatment with the PDGFR inhibitor imati-
nib, and also to IGF-1R inhibitor, NVP-AEW541, the
type A cultures displayed stem cell-like features,
including in vitro self-renewal and neurosphere for-
mation, and in vivo tumor growth. These type A
cultures were non-responsive to mono-treatments
but were growth-inhibited when exposed to a com-
bination of the two inhibitors. Furthermore, the cells’
resistance to mono-treatment was dependent on the
presence of transcription factor SOX2 (46). In a study
by Holmberg and Muhr, SOX2, OCT4, NANOG,
and KLF4 transcription factors were visualized in
high-grade human glioma tissues using immunoﬂu-
orescence techniques (47). These proteins were stud-
ied because they are able to induce pluripotent stem
cells (iPS cells) from somatic cells (48), and their
presence in glioma indicates a stemness phenotype.
The stem cell features may be part of glioma cells’
resistance to TKIs, and a combined treatment strat-
egy targeting key stem cell regulatory mechanisms and
growth factor signaling mechanisms promises to be a
useful therapeutic approach.
The role of PDGF during development
The functional signiﬁcance of the described diversity
in PDGF-A/B ligands and receptors, encoded by the
different genes, became evident from the phenotypes
of a number of genetically modiﬁed mice generated by
the groups of Christer Betsholtz and Phil Soriano (for
a review see (49)). In addition, the transcriptional
regulatory mechanisms also differ, thus providing a
basis for cell-, tissue-, and time-speciﬁc activities
in vivo. This diversity turned out to be even higher
when PDGF-C and -D were identiﬁed (8,9).
A large number of gain- and loss-of-function muta-
tions in Pdgf and Pdgfr genes have been created in
mice (50-54). The developmental defects found in
these mice underscore the importance of PDGF
ligands and receptors in normal embryonic develop-
ment. PDGF-B and b-receptors are essential for
normal blood vessel development, while PDGF
a-receptors are required for neural crest develop-
ment. PDGF-B stimulates pericytes (55) and is
involved in formation of glomeruli of the kidney.
PDGF-A is required for the normal development of
lung alveoli (50,56), intestinal villi, mesenchymal
dermis, and hair follicles. Studies in genetically mod-
iﬁed mice, where the cytoplasmic signaling domains
of the two PDGF receptors had been swapped, dem-
onstrated that PDGF receptors are partly inter-
changeable during development and mediate very
similar cellular responses (57). However, PDGFR-b
seems to have a more important intracellular signaling
capacity in the vasculature, since mice with an intro-
duced PDGFR-a signaling domain exhibited vascular
defects (58).
PDGFs are also important in adulthood, as they
are involved in wound healing, including wound
healing in the CNS (59). However, excessive or
aberrant expression of PDGFs can lead to patho-
logical responses such as atherosclerosis, ﬁbrosis,
and tumorigenesis (6).
The role of PDGF in the central nervous system
Some insights into the role of PDGFs in the CNS
were obtained before genetic mouse models were
available. Initially, our knowledge on the role of
PDGF-B and PDGFR-b in the CNS was mainly
based on their expression patterns in the brain.
PDGF-B is present in embryonic as well as in adult
neurons (60). PDGFR-b was detected in neurons,
and PDGF was shown to mediate neuroprotective
functions after injury (61-63). PDGFR-b is also
present on pericytes (64,65).
A series of in vitro studies determined that
PDGF-A is produced by neurons and astrocytes
(66-68) and acts as a mitogen for oligodendrocyte
progenitor cells (OPCs) (67,69,70). Oligodendro-
cytes differentiate postnatally from PDGFR-a–
positive OPCs. Their continued proliferation and
migration in the CNS depends on PDGF-A signaling
through PDGFR-a (71,72). In the absence of
PDGF-A, postnatally surviving mice develop tremor
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amount of PDGF-A available controls the number of
OPCs not only during embryogenesis, but also in the
adult brain (73,74).
Recent in vitro experiments demonstrated the abil-
ity of PDGF-A to induce embryonic Nestin
+ neural
progenitor cells towards becoming NG2
+ oligoden-
drocyte precursors (75). In addition, direct stimula-
tion with PDGF-A of cells in the adult lateral
ventricular wall subventricular zone (SVZ), induces
PDGFR-a–positive neural stem cells (NSCs) to give
rise to oligodendrocyte lineage cells, but not neuronal
lineage cells (76,77).
Human glioma tumors
Gliomas are the most common primary tumors of the
CNS mainly affecting adults. They are categorized
into astrocytomas, oligodendrogliomas, oligoastrocy-
tomas, and ependymomas, reﬂecting their histologic
appearance. In a clinical setting, the malignancy grade
of the tumor is an essential factor to help predict the
outcome of the patient and the choice of therapy.
According to the World Health Organization (WHO)
grading scalefor tumorsof the nervous system,lesions
with no atypia/low proliferative activities are denoted
as grade I, quite often curable upon surgical removal.
Once the lesion is inﬁltrative it is designated as grade
II, and tumors of this grade can progress to higher
grades. Grade III are lesions with accelerated mitotic
activity and nuclear atypia/anaplasia. Grade IV is the
most malignant tumor grade with a fatal outcome.
Grade IV tumors often present with inﬁltration into
surrounding tissue, high mitotic activity, characteris-
tic necrotic areas, and extensive microvascular pro-
liferations (78).
Diffuse astrocytomas grade II and III may prog-
ress to grade IV, which is then referred to as sec-
ondary glioblastoma (GB). However, the majority of
GB tumors develop de novo, with no previous his-
tory, and are referred to as primary glioblastomas
(78). The primary and secondary GBs exhibit the
same histopathologic characteristics, even though
they differ in both genetic changes and clinical
history (79).
Activated growth factor pathways in glioma
A frequent hallmark of malignant gliomas is activation
of RTK signaling pathways, most commonly caused
by EGFR mutation/ampliﬁcation or PDGFR ampli-
ﬁcation/overexpression. EGF/TGF-a and PDGF
proteins exert their activity by binding to and activat-
ing cell surface tyrosine kinase receptors, which leads
to receptor dimerization, transphosphorylation, and
subsequent activation of intracellular signaling path-
ways, such as PI3K/AKT and RAS/MAPK.
Ampliﬁcation of EGFR is found in about 43% of
primary GBs and is associated with EGFR overex-
pression. However, EGFR overexpression has rarely
been found in secondary GBs (79-83). Furthermore,
70%–90% of all GBs with EGFR overexpression have
rearrangements of the gene (82). The most wide-
spread mutated variant of EGFR is EGFRvIII, which
contains a 267-bp deletion of exons 2–7 in the extra-
cellular domain, resulting in ligand-independent acti-
vation of the receptor (79,83-85).
Overexpression/hyperactivity of PDGF ligands and
receptors are frequent events in human gliomas of all
grades (33,35,86,87), and their expression pattern in
tumors suggests the presence of autocrine and para-
crine stimulatory loops (36,40). Ampliﬁcation of
PDGF and PDGFR genes is not as common as the
ampliﬁcation of EGFR (36,39) and occurs only in
11% of GBs. However, this still makes PDGFRA the
second most frequently ampliﬁed RTK gene in these
tumors (82). Activating rearrangements of PDGFRA
in GBs is very rare. Previously, only two reports
described an in-frame deletion of the Ig-like domain,
the PDGFRA
D8,9 mutant and a mutation in the
C-terminal of PDGFRA (88,89). Recent sequencing
analysis of GBs has identiﬁed several point mutations
in the Ig-like domains (90), and another study dis-
covered a gene fusion between PDGFRA and the
kinase insert domain receptor (KDR/VEGFR2)
gene (91). Ozawa and colleagues have also demon-
strated that the previously discovered PDGFRA
D8,9
mutant is present in 40% of GBs with PDGFRA
ampliﬁcation.
Alterations in other RTK genes have been reported,
including ERBB2/HER2 mutations and MET ampli-
ﬁcations in 8 and 4% of GBs analyzed, respectively
(82).
High levels of active RAS have been reported in
high-grade astrocytomas, but unlike in many cancers
mutated RAS is rarely present in malignant gliomas
(2%) (82). Neuroﬁbromin-1 (NF1) is a tumor sup-
pressor and a negative regulator of RAS. Mutations of
NF1 have been linked to the hereditary condition
neuroﬁbromatosis type-1, where patients are predis-
posed to glioma development (92). NF1 was recently
found to be mutated in 18% of glioblastomas (82).
Activation of PI3K/AKT signaling can be achieved
by loss of the tumor suppressor gene PTEN or by
mutations in PIK3CA. PTEN is a direct antagonist of
the activity of PI3K. PTEN loss is rare in low-
grade gliomas, but mutations and deletions are found
in 50% of high-grade gliomas (93) and are associated
with poor patient survival. As a result, inactive PTEN
leads to AKT hyperactivation, which in turn triggers
PDGF and PDGF receptors in glioma 103downstream pathways supporting cellular growth
(through mTOR) and proliferation (through inhibi-
tion of GSK3-b) (94).
Loss of cell cycle regulation in glioma
The tumor suppressor protein p53 is a major regulator
ofmultiplecellularresponses,includingthoseinduced
by DNA damage, oncogene activation, and hypoxia
(95).InGBs,TP53isfoundtobemutatedin35%ofall
cases (82). It has been described that somatic TP53
mutations are more common in low-grade astrocyto-
mas and secondary GBs than in primary GBs and that
the spectrum of mutations is different (79,96). How-
ever, recent studies have conﬁrmed that TP53 muta-
tions are also prevalent in primary GBs (97,98). In
addition, chromosome 17p is an early and frequent
target for LOH in both low-grade and high-grade
gliomas (99,100). Inactivation of p53 can also occur
through other mechanisms such as viral infection,
loss of ARF, or overexpression of MDM2 (101). The
progression from G1 to S phase in the cell cycle is
controlled by the p16INK4A/CDK4/RB1 pathway.
Genetic alterations involving this pathway are found
in 78% of glioblastomas (82).
Molecular-genetic subclassiﬁcation of
high-grade glioma
Previous clinical and genetic studies of GBs described
two subtypes, primary and secondary. However,
recent genomic studies have provided more detailed
information about the molecular mechanisms
involved in glioma initiation and progression and
have identiﬁed new subgroups based on glioma mole-
cular signatures (82,97,102-104) that are described as
classical, mesenchymal, proneural, and neural sub-
types. Among these subtypes, the proneural subtype is
characterized by PDGFRA ampliﬁcation and loss or
mutation of TP53, CDKN2A, and PTEN. Mutation
of the isocitrate dehydrogenase 1 gene (IDH-1) (see
below) and activation of PI3K and PDGFR-a path-
ways are also frequent characteristics of this subtype.
GBs of the secondary subtype have gene expression
proﬁles corresponding to those of neuronal (SOX2,
DCX, etc.) and oligodendrocytic (PDGFRA, OLIG2,
etc.) progenitor cells. These ﬁndings have been com-
prehensively discussed (90,105,106). In addition to
distinct genomic proﬁles, the classical, mesenchymal,
and proneural subtypes vary in their biological
behavior and response to adjuvant treatments (107).
Recent results from GB tumor DNA sequencing
studies also revealed previously unknown important
genetic changes. Spontaneous mutations of IDH-1
and IDH-2 appeared as strong prognostic indicators
in anaplastic astrocytoma and secondary GB. In
patients with secondary GB, mutation of IDH-1 is
linked to a median survival of 31 months compared
to 15 months for the group of patients with wild-type
(WT) IDH-1 (104). Importantly, these mutations also
occur together with TP53 mutations in lower-
grade tumors.
Neural stem cells
A common belief of classical neuroscience was that
once development was completed, no new neurons
were produced. However, this view has changed,
and in the 1960s the ﬁrst evidence of adult neuro-
genesis appeared from studies in rat brain (108).
During brain development, neuroepithelial stem
cells situated in the ventricular zone of the lateral
ventricle wall give rise to neurons and glia. Even
though it was thought that neurogenesis is mostly
completed by birth, it continues throughout life.
Cells, commonly known as neural stem cells
(NSCs), have a capacity to self-renew and differen-
tiate along multiple lineages, contributing to tissue
maintenance and regeneration in case of injury in
the adult CNS (109,110).
There are two brain areas in mice where adult
NSCs are known to reside, the SVZ of the lateral
ventricle and the subgranular zone (SGZ) of the
dentate gyrus in the hippocampus. The largest source
of NSCs in the adult mammalian brain is the SVZ,
which is described as a thin layer of proliferative
cells in the lateral wall of the lateral ventricle
(109,111-113). Adult NSCs are not unstructured
undifferentiated cells; they show features of differen-
tiated astrocytes and express glial ﬁbrillary acidic
protein (Gfap). This subpopulation of Gfap
+ cells
in the SVZ (B cells) produces a transit-amplifying cell
population (C cells) that then gives rise to migratory
neuroblasts (A cells) and OPCs. It has been shown
that adult NSCs are derived from radial glia, the stem
cells of the developing brain, which in turn are
derived from the neuroepithelium (114). In addition
to Gfap, NSCs are characterized by expression of
Nestin (112). Sox2 is also found in NSCs of the SVZ
(115) and SGZ (116) and is required to maintain the
immature state of NSCs and to preserve their capa-
city to proliferate and generate neurons (117,118).
There are several architectural elements contribut-
ing to adult neurogenesis, such as localization of
NSCs near the cerebrospinal ﬂuid, close association
with blood vessels, a rich extracellular matrix (ECM),
specialized basal lamina, and widespread cell-to-cell
interactions (119,120). The endothelial cells of blood
vessels release factors that promote the self-renewal of
NSCs (121,122).
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It was demonstrated that a fraction of SVZ stem cells
express PDGFR-a (76) and that EGFR is expressed
in type B and type C cells (123). It has also been
shown that NSCs proliferate in response to both
PDGF and EGF in vitro (110,112,124,125), and
EGF is used in cultures to keep NSCs in an undif-
ferentiated state (110). Infusion of EGF into the brain
results in a signiﬁcant ampliﬁcation of endogenous
SVZ precursor cells (123,124,126) and promotes
oligodendrogenesis (127). When active EGF receptor
was introduced into Ink4a/Arf-deﬁcient mice, it
caused dedifferentiation of astrocytes, and high-grade
gliomas developed from both dedifferentiated astro-
cytes and NSCs carrying the same genetic alteration
(128). PDGF also has a dedifferentiating effect on
mouse astrocytes (129), and infusion of PDGF-A into
the lateral ventricle of adult mouse brain can induce
the proliferation of PDGFR-a–positive NSCs that
may form glioma-like lesions (76).
The tumor suppressor p53 plays an important role
during development of the CNS by inducing apo-
ptosisofneurons and neural progenitors to adjust the
cell number (130), and a subset of Trp53-deﬁcient
mice develop exencephaly (131,132). P53 is present
in the adult mouse lateral ventricle wall SVZ and
regulates NSCs proliferation, apoptosis, and self-
renewal. Gene expression proﬁling identiﬁed several
genes that were down-regulated in Trp53 null NSCs
in vitro, such as the cell cycle regulatory factors
p21 and p27 (133).
Cancer stem cells; heterogeneity of glioma cells
The heterogeneity of glioblastoma cells has become
increasingly appreciated as a signiﬁcant factor, allow-
ing for paracrine stimulatory mechanisms in tumors
(134). It has also been shown that within some tumors
there is a subset of cancer cells (CSCs) with stem cell-
like features: unlimited self-renewal, multipotency,
and tumor-initiating capacity in vivo. These cells
may give rise to a number of new cell types in the
tumor and maintain the neoplastic growth over time.
CSCs have been described in brain tumors (135-140).
A high rate of recurrence and resistance to treat-
ment are major characteristics of malignant gliomas.
It has been reported that brain CSCs have the capacity
to survive treatment and give rise to a new tumor with
characteristics of the original tumor (141). Since the
adult brain has only a limited population of prolifer-
ating cells that are able to accumulate the several
mutations required for transformation into a cancer
cell, the adult NSCs/progenitor cells have been
suggested as candidate sources for brain CSCs
(Figure 2). In addition, it has been suggested that
tumorigenic events can lead to dedifferentiation of a
mature cell and thereby gain of stem cell properties
(Figure 2) (128,129,142). NSCs are relatively quies-
cent cells, whereas glioblastoma cells are highly pro-
liferative. It is therefore possible that the majority of
tumor cells represent rapidly amplifying progenitors
rather than stem cells.
Similar to NSCs, brain CSCs are located in a
special microenvironment. They are found in close
proximity to blood vessels, often in hypoxic areas
(143). They have been shown to stimulate angiogen-
esis by secreting VEGF (144), and in return they
receive a constant supply of nutrients and oxygen
(145). Glioma cells migrate along the tumor vessels
into the surrounding tissue. Other components of the
perivascular niche, such as adhesion to the surround-
ing cells or ECM are important for CSCs main-
tenance. L1CAM, a cell surface molecule that
intervenes in cell–ECM and cell-to-cell interactions,
was found to be highly expressed in glioma CSCs
(146,147).
PDGF-driven glioma models
To address the functional role of PDGF in brain
tumors, several experimental models have been cre-
ated to induce gliomas, mostly in mice by forced
expression of PDGF. In general, overexpression of
PDGF in the brain leads to excessive production of
OPCs and, if in a permissive setting, results in mainly
oligodendroglioma-like tumors.
The ﬁrst attempt to model ‘PDGF-induced’ glioma
was made by Deinhardt (148), who injected SSV,
with the v-sis oncogene, into the brains of newborn
marmosets. This resulted in gliomas, morphologically
indistinguishable from human tumors, described in a
review by Nistér and Westermark (149). Many years
later, when a PDGF-B-encoding retrovirus was used
for injection in newborn mice, highly malignant brain
tumors developed in 40% of all animals, and further
in vitro experiments showed that autocrine PDGF
stimulation was an important step in their generation
(150,151).
As an alternative approach, the RCAS/TV-A model
system was developed for brain tumor studies
(152,153) and has been successfully used to assess
the signiﬁcance of PDGF and downstream signaling
mechanisms in glioma. Tumor progression can be
enhanced in the PDGF-induced glioma models by
combination of another genetic aberration such as
loss of Ink4a/Arf, Trp53,o rPten (154-156). However,
a disruption of the homology-directed DNA repair
mechanism, by introduction of RAD51, decreases
PDGF and PDGF receptors in glioma 105PDGF-B-induced tumor incidence and progression
(157).
In order to test the tumorigenic potential of adult
glial progenitors, PDGF-B was retrovirally expressed
in rat corpus callosum, leading to transformation
of NG2-positive OPCs and development of GBs
(158). Injection of retroviral PDGF-B in newborn
rats causes a shift in the differentiation fate of
the NSCs, generating more pdgfr-a/NG2/Olig2-
expressing OPCs that do not differentiate into
mature oligodendrocytes (159). Moreover, excessive
expression of PDGF-B in neural progenitor cells
forced their respeciﬁcation towards the oligoden-
droglial lineage with development of highly malig-
nant oligodendroglial tumors in mice (160,161).
Different capacities of PDGF-B and PDGF-AL
in brain tumor development
To investigate the roles of PDGF-B and PDGF-A in
brain tumor development, two transgenic mouse
models were generated in which overexpression of
human PDGF-B (162) and PDGF-AL (163), respec-
tively, was induced in astrocytic cells of the brain by a
human GFAP promoter fragment. Both these PDGF
proteins have the C-terminal motif, attaching them to
the ECM, but while PDGF-B binds to both a- and
b-receptors, PDGF-AL binds only to the a-receptor.
The GFAP promoter fragment used is active during
embryogenesis, in radial glial cells of the telenceph-
alon and in the cerebellar anlage, and stays active
postnatally in astrocytic cells, including activity in
astrocytic cells of the adult SVZ. The effects of
PDGF-AL and PDGF-B were found to be different.
The PDGF-B-overexpressing transgenic mice did
not develop brain tumors, and the mice were pheno-
typically normal. They were therefore crossed with
Trp53 null mice to obtain PDGF-B/p53-null off-
spring. In this way, two aberrations commonly pres-
ent together in human gliomas could be combined.
On the Tp53 null background, two PDGF-B trans-
genic mouse lines developed brain tumors at high
rates, 68 and 43%, and tumors occurred between
2 and 6 months after birth. They spread diffusely
throughout the brain tissue and displayed microvas-
cular proliferations as well as necroses lined by pali-
sading cells. Thus, morphologically the tumors had
the characteristics of human GB. According to pre-
vious ﬁndings from human brain tumors, PDGFR-a
is localized on glial tumor cells, and PDGFR-b on the
vasculature (35). This was also the case in the PDGF-
B/p53-null tumors that were generated. The majority
of glioma cells proper, but not the tumor vasculature,
expressed the transgene, and together this indicated
the possibility of both autocrine and paracrine stim-
ulatory loops similar to those in human tumors (162).
Small Gfap
+/Nestin
+ SVZ lesions were present in the
lateral ventricular wall and were suggested to repre-
sent a point of origin. Due to the variable location of
the tumors and the fact that the PDGF-B transgene
was produced by astrocytic cells throughout the brain,
such as in the glia limitans, and not only in the SVZ,
another suggested possibility was that astrocytes dedi-
fferentiated and transformed into tumor cells. Larger
NSC
NSC
NSC
CSC
PC
PC DC
De-differentiation
Figure 2. Three possible ways for a cancer stem cell (CSC) to arise: a neural stem cell (NCS) acquires a mutation; a progenitor cell (PC)
acquires two or more mutations; or a fully differentiated cell (DC) undergoes several mutations that transform and drive it back to a stem-
like state.
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and developed the characteristic glioma vasculature
and necroses. Thus, sustained overexpression of
PDGF-B in astrocytic cells can, on a Tp53 null back-
ground, lead to uncontrolled expansion of Pdgfr-a
+
glial progenitor cells and initiate the development of
aggressive GB-like brain tumors.
Whereas the PDGF-B overexpressing transgenic
mice were phenotypically normal, with survival times
that did not differ from WT mice, PDGF-AL-over-
expressing mice developed a characteristic, lethal
phenotype, after approximately 6 weeks (163). A
microscopic analysis of brain tissue showed an
increased cellularity due to a highly proliferating,
expanding mixed population of astrocytic and
OPC-like cells, that spread diffusely throughout the
brain and that was also concentrated in distinct brain
areas, which overlapped with the areas of transgene
activity, including: the roof of the lateral ventricles, in
corpus callosum, on the outer surface of the brain,
and in the cerebellum. Closely associated with the
Gfap
+ astrocytic cells were these OPC-like cells
with the presence of the oligodendrocyte markers,
Pdgfr-a/Olig2/NG2.
A few of the PDGF-AL mice presented with very
advanced lesions, in the form of a heavy diffuse inﬁl-
trationofcellsthroughoutthewholebrain,comprising
mostlyofwhitematterareasandalsointheformofpial
outgrowths with excessive masses of mitotic and atyp-
icalcells.Alsohere,thecellpopulationwasmixed,with
Gfap
+andPdgfr-a
+/Olig2
+/NG2
+cells.Theselesions
were associated with long, angulated and thick-walled
capillarystructures,stronglypositiveforPdgfr-b.Thus,
these lesions were found to be similar to human ana-
plastic oligoastrocytomas (grade III).
The majority of Olig2
+/Pdgfr-a
+ cells in the exam-
ined PDGF-AL brain sections did not express Gfap or
the transgene. This observation could be due to the
fact that the PDGF-AL transgene produced by NSCs/
astrocytic cells stimulated OPCs in a paracrine fash-
ion, or indirectly via changing the cell fate of the NSC/
astrocytic progenitor. Additional experiments are
required to resolve this issue.
Because PDGF-AL has a C-terminal retention
motif that makes it associate with ECM and possibly
with the surface of the producing cell, one would
expect that its area of action is rather limited.
Pdgfr-a is normally expressed by glial progenitor cells
(164,165), and as discussed previously PDGF-A is a
potent mitogen for OPCs (71,72,74). PDGF-A can
also inﬂuence cell fate decisions of cells located in the
adult SVZ by inducing them to become OPCs rather
than neurons. These cells are sensitive to alterations
in the PDGF pathway and can form hyperplasias in
response to PDGF-AS, as mentioned previously (76).
In summary, our research work and that of others
demonstrate that overexpression of PDGF-AL in
astrocytic cells can induce oligoastrocytoma-like
lesions at a low rate. Hyperactive production of
PDGF-AL in the brain has distinct and strong effects
that are different from previously described effects of
PDGF-AS and PDGF-B. PDGF-B, in spite of it being
expressed in the SVZ by astrocytic cells and carrying
the C-terminal retention motif similar to PDGF-AL,
resulted in a normal phenotype. It cannot be excluded
that the difference was a matter of local concentra-
tions of growth factor. However, the fact that con-
current loss of p53, a known regulator of stem cell
self-renewal resulted in heavy ampliﬁcation of a more
undifferentiated Nestin
+/mostly Gfap
- neural cell
type, forming GB-like tumors, suggested a difference
in the capacity of progenitors to respond to the PDGF
proteins.
In conclusion, the role of PDGF-A that was shown
in this model system is consistent with the PDGFRA
overexpression observed in human low-grade glio-
mas, whereas the role of PDGF-B was to promote
the full-blown vascular proliferations that are charac-
teristic of human GBs. The loss of p53 function may
in addition have allowed for enhanced self-renewal of
early neural progenitors. SVZ cells are known to be
affected by loss of p53 (166).
We speculate that in the human situation, the early
and almost ubiquitous TP53 mutations/deletions on
chromosome 17p observed in low-grade astrocytic
glioma may similarly allow for the emergence of
stem cell features during glioma progression. Addi-
tional experiments are required to resolve this issue.
Final comment
It has been an honor to participate in the research
work on platelet-derived growth factors. It is also
stimulating to think of the extensive technical devel-
opments and the progress made in the ﬁelds of normal
brain development and glioma biology over the last
30 years, and look forward to further developments
that may improve the therapy of brain tumor patients.
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